WO1998037916A1 - Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique - Google Patents
Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique Download PDFInfo
- Publication number
- WO1998037916A1 WO1998037916A1 PCT/FR1998/000389 FR9800389W WO9837916A1 WO 1998037916 A1 WO1998037916 A1 WO 1998037916A1 FR 9800389 W FR9800389 W FR 9800389W WO 9837916 A1 WO9837916 A1 WO 9837916A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- complex
- compound
- active substance
- formula
- Prior art date
Links
- -1 lipid compounds Chemical class 0.000 title claims abstract description 51
- 239000013543 active substance Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims description 50
- 108091033319 polynucleotide Proteins 0.000 title claims description 23
- 102000040430 polynucleotide Human genes 0.000 title claims description 23
- 239000002157 polynucleotide Substances 0.000 title claims description 23
- 238000012546 transfer Methods 0.000 title claims description 9
- 230000001225 therapeutic effect Effects 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 22
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 22
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 22
- 125000002091 cationic group Chemical group 0.000 claims abstract description 20
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 150000003254 radicals Chemical class 0.000 claims abstract description 11
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 8
- 239000002202 Polyethylene glycol Chemical group 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 229920001223 polyethylene glycol Chemical group 0.000 claims abstract description 5
- 150000005840 aryl radicals Chemical group 0.000 claims abstract description 3
- 125000003827 glycol group Chemical group 0.000 claims abstract description 3
- 125000006353 oxyethylene group Chemical group 0.000 claims abstract description 3
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 68
- 150000002632 lipids Chemical class 0.000 claims description 57
- 108020004414 DNA Proteins 0.000 claims description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 26
- 238000001890 transfection Methods 0.000 claims description 24
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 13
- 230000007935 neutral effect Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000003599 detergent Substances 0.000 claims description 9
- 238000001415 gene therapy Methods 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 210000000663 muscle cell Anatomy 0.000 claims description 6
- 229920000768 polyamine Polymers 0.000 claims description 6
- 210000005058 airway cell Anatomy 0.000 claims description 5
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000001533 respiratory mucosa Anatomy 0.000 claims description 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 230000000799 fusogenic effect Effects 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 102000006240 membrane receptors Human genes 0.000 claims description 3
- 108020004084 membrane receptors Proteins 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 2
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 claims description 2
- BQCCJWMQESHLIT-UHFFFAOYSA-N 1-propylsulfinylpropane Chemical compound CCCS(=O)CCC BQCCJWMQESHLIT-UHFFFAOYSA-N 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- 108091005461 Nucleic proteins Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 238000012387 aerosolization Methods 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- 229930183167 cerebroside Natural products 0.000 claims description 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003677 chloroquine Drugs 0.000 claims description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- 230000030648 nucleus localization Effects 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 2
- 108020004418 ribosomal RNA Proteins 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 150000001767 cationic compounds Chemical class 0.000 abstract description 7
- 150000001450 anions Chemical class 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 108060001084 Luciferase Proteins 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 6
- HYCFMQFSFAFSRL-UHFFFAOYSA-N tert-butyl n-[4-(3-aminopropylamino)butyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CCCCNCCCN HYCFMQFSFAFSRL-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229940063673 spermidine Drugs 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- QQWYQAQQADNEIC-RVDMUPIBSA-N tert-butyl [(z)-[cyano(phenyl)methylidene]amino] carbonate Chemical group CC(C)(C)OC(=O)O\N=C(/C#N)C1=CC=CC=C1 QQWYQAQQADNEIC-RVDMUPIBSA-N 0.000 description 4
- AGIUPQUTLBAVDK-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)-n-[4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCCN(CCCN)C(=O)OC(C)(C)C AGIUPQUTLBAVDK-UHFFFAOYSA-N 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000010189 intracellular transport Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- SXSUKFQJCFUOTC-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)-n-[4-[3-aminopropyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butyl]carbamate Chemical compound CC(C)(C)OC(=O)N(CCCN)CCCCN(CCCN)C(=O)OC(C)(C)C SXSUKFQJCFUOTC-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- LMIHXHFNDFTHPF-UHFFFAOYSA-N 2,2-diamino-4-(9H-fluoren-9-ylmethoxy)-3-(9H-fluoren-9-ylmethoxycarbonyl)-4-oxobutanoic acid Chemical compound C(=O)(OCC1C2=CC=CC=C2C2=CC=CC=C12)C(C(C(=O)O)(N)N)C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C12 LMIHXHFNDFTHPF-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- ZIKHESFFYFUBTA-UHFFFAOYSA-N NCCCCN.C(CC)#N.C(CC)#N Chemical compound NCCCCN.C(CC)#N.C(CC)#N ZIKHESFFYFUBTA-UHFFFAOYSA-N 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241001441550 Zeiformes Species 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000008505 β-D-glucopyranosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Definitions
- the present invention relates to new lipid compounds and novel compositions comprising them. More particularly, the present invention relates to the use of said compounds or of said compositions for preparing a transfer vector for an active substance, in particular therapeutically comprising negative charges, in particular a polynucleotide, in a target cell, particularly a vertebrate cell, and more particularly of mammal.
- the first category relates to physical techniques such as microinjection, electroporation or particle bombardment which, although effective, are largely limited to in vitro applications and the implementation of which is cumbersome and delicate.
- the second category calls upon techniques relating to molecular and cellular biology for which the gene to be transferred is associated with a vector of biological or synthetic nature which favors the introduction of the latter.
- the most effective vectors are viral vectors, in particular adenoviral or retroviral.
- viruses have already been the subject of numerous studies and some of them are already used on an experimental basis as gene vectors in humans for the purpose of, for example, vaccination, immunotherapy or therapy aimed at compensating for a genetic deficiency.
- Non-viral methods include coprecipitation with calcium phosphate, the use of receptors mimicking viral systems (for a review see Cotten and Wagner, 1993, Current Opinion in Biotechnology, 4, 705-710), or the use of polymers such as polyamidoamine (Haensler and Szoka, 1993, Bioconjugate Chem., 4, 372-379), or of a polymer such as those presented in WO 95/24221 describing the use of dendritic polymers, the document WO 96/02655 describing the use of polyethylene imine, or polypropylene imine and documents US-A-5,595,897 and FR 2,719,316 describing the use of polylysine conjugates.
- liposomes the advantage of which as an agent allowing the introduction, inside cells, of certain biological macromolecules, such as for example DNA, l RNA, proteins or certain pharmaceutically active substances has been widely described in the literature.
- certain biological macromolecules such as for example DNA, l RNA, proteins or certain pharmaceutically active substances has been widely described in the literature.
- cationic lipids which have a strong affinity for cell membranes and / or nucleic acids.
- DOTMA DOTMA
- DOGS or Transfectam TM Behr et al., 1989, PNAS, 86, 6982-6986
- DMRIE and DORIE DMRIE and DORIE
- DC-CHOL Gao and Huang, 1991, BBRC, 179, 280-285
- DOTAPG McLachlan et al., 1995 , Gene Therapy, 2,674-622
- Lipofectamine ⁇ as well as those described in patent applications WO9116024 or
- R 7 is H, spermine, spermidine, histone, a protein, an amino acid, a polypeptide.
- lipids which can be in cationic form, useful in particular for transferring an active substance, in particular therapeutically containing negative charges, in particular a polynucleotide, inside a target cell, including one can envisage the use in particular in vivo within the framework of a gene therapy.
- residues R are, independently of each other, a hydrogen atom or a group of formula II:
- alkenyl is understood to mean that the carbon chain can comprise one or more double bond (s) along the said chain.
- the invention relates to a compound selected from the compounds of formulas:
- R is a group of formula II as defined above and H 2 N - [- (CH 2 ) m -NR] n-1 - (CH 2 ) m -NH 2 Illb in which:
- R has one of the meanings indicated for formula I provided that at least one R is a group of formula II and for each of the formulas: n is a positive integer from 1 to 6, m is a positive integer of 1 to 6 which can be different for each motif - (CH 2 ) m , and more particularly for each motif - (CH 2 ) m -NR- when n> 1.
- the compounds of formula IIIb contain one or two R groups of formula II.
- - n is an integer chosen from the numbers 2, 3 or 4,
- - m is an integer chosen from the numbers 2, 3 or 4.
- R t and R 2 are radicals of 6 to 10 carbon atoms, but in this case it is preferable to choose compounds for which the number of R groups of formula II is 2, 3 or 4.
- the lipids according to the invention are chosen from the group consisting of the compounds of the following formulas:
- R 3 and R 4 are protective groups, in particular Fmoc (Grandas et al., 1989, Int. Journal pept. Prot. Res. Vol 33, 386-390) with an amine of formula:
- R 5 NH [(- CH 2 ) m -NR 5 ] n - ⁇ - (CH 2 ) m NHR 5 VI m, n having the same meaning as for formula I, R 5 being a protective group, in particular t- butoxycarbonyl (BOC) or a hydrogen atom, at least one of the radicals R 5 and at most four of the radicals R 5 corresponding to the hydrogen atom.
- R 5 being a protective group, in particular t- butoxycarbonyl (BOC) or a hydrogen atom, at least one of the radicals R 5 and at most four of the radicals R 5 corresponding to the hydrogen atom.
- the NR 3 , -NR 4 functions are then deprotected to fix, by amidation or alkylation, the radicals Ri and R 2 in a known manner, in particular by the action of the corresponding ester -N- hydroxysuccinimide.
- the compound obtained is deprotected in the presence of trifluoroacetic acid.
- the amines of formula VI are prepared in a known manner.
- the compound of formula VI is 1-4 di-boc-spermidine
- the methods described are generally applicable to syntheses of the compounds according to the invention subject to adaptations within the reach of the skilled person.
- the compounds of the invention cannot be limited to those obtained by the methods of preparation described above.
- the compounds according to the invention can also be substituted. Such substitutions may in particular consist of into a labeling molecule (see labeling molecules in US 4711955) which makes it possible, for example, to visualize the distribution of the compounds or complexes containing them after administration - in vitro or in vivo, a cell targeting molecule, an anchoring molecule.
- the invention therefore also relates to a compound as presented above conjugated to one or more targeting elements, also called ligands of interest, via at least a) one of the carbon atoms, in particular chosen among those present on the groups Ri and / or R 2 , or b) one of the secondary or primary nitrogen atoms of the polyamine chain or of the diaminocarboxylic acid.
- Such elements can allow targeting to a particular cell type, facilitate penetration inside the cell, lysis of endosomes or even intracellular transport and are widely described in the literature. It may, for example, be all or part of sugars, peptides (GRP peptide, Gastrin Releasing Peptide, for example), oligonucleotides, lipids, hormones, vitamins, antigens, antibodies, specific ligands for membrane receptors, ligands capable of reacting with an anti-ligand, fusogenic peptides, nuclear localization peptides, or a combination of such compounds.
- Such conjugates can be easily obtained according to the techniques widely described in the literature, and more particularly by chemical coupling, in particular by using protective groups such as trifluoroacetyl or Fmoc or Boc on the polyamine and more particularly by using one or more orthogonal protective groups such as those described in Protective Groups in Organic Synthesis (p. 309-406, 1991, eds. TW Greene, PGM Wuts, Wiley) on polyamine or diaminocarboxylic acid. Selective deprotection of a protective group then makes it possible to couple the targeting element, and the lipid is then deprotected.
- protective groups such as trifluoroacetyl or Fmoc or Boc
- one or more orthogonal protective groups such as those described in Protective Groups in Organic Synthesis (p. 309-406, 1991, eds. TW Greene, PGM Wuts, Wiley) on polyamine or diaminocarboxylic acid.
- said compound is in cationic form, that is to say that it is in protonated form by attachment of a proton to one or more nitrogen atoms present on the polyamine chain.
- said cationic lipid is associated with one or more biologically acceptable anions, such as for example the trifluoroacetate, halide, halide, monomethylsulfate, acetate or phosphate, iodide, chloride, bromide ... anion.
- biologically acceptable anions such as for example the trifluoroacetate, halide, halide, monomethylsulfate, acetate or phosphate, iodide, chloride, bromide ... anion.
- the invention also relates to a composition
- a composition comprising at least one compound as described above and optionally at least one adjuvant capable of improving the formation of complex between said compound and an active substance, or of improving the functioning of these complexes vis-à-vis the cell.
- such an adjuvant will be a neutral or zwitterionic lipid, such as for example a lipid which is or derived from a triglyceride, a diglyceride, cholesterol (see for example US 5,438,044), in particular, a neutral or zwitterionic lipid which is or which is derived from a phosphatidyl ethanolamine - (PE), phosphatidylcholine, phosphocholine, sphyngomyelin, ceramide or cerebroside.
- PE phosphatidyl ethanolamine -
- DOPE dioleoylphosphatidyl ethanolamine
- the weight ratio between the compound of the invention and the neutral or zwitterionic lipid is generally between 0.1 and 10, it being understood that this ratio may vary depending on the nature of the components considered. Those skilled in the art have sufficient knowledge to allow these minor adaptations. It is also possible to use a mixture of neutral and / or zwitterionic lipids or else a mixture of cationic lipids and neutral and / or zwitterionic lipids.
- the invention further relates to a complex comprising at least one compound or at least one composition as described above and at least one active substance, in particular therapeutically comprising at least one negative charge. According to a variant of the invention, said complex can also contain one or more cationic amphiphiles such as those described in the literature, examples of which have been proposed above.
- said active substance is chosen from nucleic acids and proteins.
- the active substance of the complex according to the invention is a polynucleotide, said compound or said composition then making it possible to improve the transfecting power of the polynucleotide in a cell.
- polynucleotide designating a fragment of DNA and / or RNA, double strand or single strand, linear or circular, natural isolated or synthetic, designating a precise sequence of nucleotides, modified or not (see title example US 5525711), branded or not (see, for example, US 4711955 or EP 302175), making it possible to define a fragment or a region of a nucleic acid without limitation of size.
- polynucleotide is intended to denote in particular a cDNA, a genomic DNA, a plasmid DNA, " a messenger RNA, an antisense RNA, a ribozyme, a transfer RNA, a ribosomal RNA, or a DNA coding for such RNA.”
- Polynucleotide " or “nucleic acid” are synonymous terms in the context of the present application.
- Anti sense means a nucleic acid having a sequence complementary to a target sequence, for example a sequence of ⁇ RNm which one seeks to block the expression by hybridization on the target sequence, and by "sense", a nucleic acid having a sequence homologous or identical to a target sequence, for example a sequence which binds to a protein transcription factor and is involved in the expression of a given gene.
- said polynucleotide comprises a gene of interest and elements allowing the expression of said gene of interest. said polynucleotide is advantageously in the form of a plasmid.
- the elements allowing expression are the set of elements allowing the transcription of said DNA fragment into RNA (antisense RNA or mRNA) and the translation of mRNA into polypeptide.
- These include promoter sequences and / or regulatory sequences effective in said cell, and optionally the sequences required to allow excretion or expression on the surface of target cells of said polypeptide.
- the promoters such as the promoters of the RSV, MPSV, SV40, CMV or 7.5k viruses, of the vaccinia virus, the promoters of the gene coding for muscle creatine kinase, for actin, for the lung surfactant.
- said polynucleotide can comprise at least two sequences, identical or different, having transcriptional promoter activity - and / or at least two DNA coding sequences, identical or different, located in relation to one another in a contiguous, distant manner, in the same direction or in the opposite direction, provided that the function of transcriptional promoter or transcription of said sequences is not affected.
- this type of nucleic acid construction it is possible to introduce “neutral” nucleic sequences or introns which do not affect transcription and are spliced before the translation step.
- polynucleotide may also contain sequences required for intracellular transport, for replication and / or for integration. Such sequences are well known to those skilled in the art.
- polynucleotides according to the present invention can also be polynucleotides modified so that it is not possible for them to integrate into the genome of the target cell or polynucleotides stabilized using agents, such as for example spermine.
- the polynucleotide can be homologous or heterologous to the target cell. It may be advantageous to use a polynucleotide which codes for all or part of a polypeptide, in particular a polypeptide exhibiting a therapeutic or prophylactic activity, and more particularly an immunogenic activity of the cellular or humoral type.
- polypeptide is understood without restriction as to its size or its degree of modification (for example of glycosylation).
- a factor for regulating transcription, translation, replication, stabilization of the transcripts or an antibody, such as for example the gene coding for the protein CFTR, dystrophin, factor VIII or IX, E6 / E7 of HPV, MUC1, BRAC1, the interferon ⁇ , the interferon " ⁇ , interleukin (IL) 2, IL-4, IL-6, IL-7, IL-12, tumor necrotizing factor (TNF) alpha type, GM-CSF (Granulocyte Macrophage Colony Stimulating Factor), the tk gene of the Herpes Simplex virus type 1 (HSV-1), the gene associated with retinoblastoma or p53 or all or part of immunoglobulins, such as the fragments F (ab) 2 , Fab ', Fab or anti-idiotypes (US 4,699,880) Of course, this list is not exhaustive and other genes can be used.
- the complexes according to the invention are small (less than 500 nm, advantageously 200 nm and preferably 100 nm). Furthermore, the transfection experiments carried out show that advantageously the weight ratio of the lipid compound according to the invention to said polynucleotide is from 0.01 to 100. The optimal ratio is from 0.05 to 10.
- the invention also relates to a process for the preparation of the cationic compound / anionic active substances complexes, the said process being characterized in that one or more lipids in cationic form or a composition according to the invention are present in which the lipid is under cationic form with one or more active substances comprising at least one negative charge and in that said complex is recovered, possibly after a purification step. It also relates to kits for preparing such complexes comprising one or more lipids or one or more compositions according to the invention.
- one or more cationic compounds are dissolved with an appropriate quantity of solvent or mixture of solvents miscible in water, in particular ethanol, dimethylsulfoxide (DMSO), or preferably a 1: 1 ethanol / DMSO mixture (v: v), so to form lipid aggregates according to a known method described for example in patent application WO-A-9603977, or according to a second variant, are suspended with an appropriate amount of a detergent solution such as an octylglucoside such as n -octyl ⁇ -D-glucopyranoside, or 6- 0- (N-heptylcarbomoyl) -methyl- ⁇ -D-glucopyranoside.
- a detergent solution such as an octylglucoside such as n -octyl ⁇ -D-glucopyranoside, or 6- 0- (N-heptylcarbomoyl) -methyl- ⁇ -D-glucopyranoside.
- the suspension can then be put in a buffer medium and mixed with a solution of active substance containing negative charges.
- a neutral or zwitterionic lipid is present in the final complex, a known manner is formed before being dissolved in the water-miscible solvent or in the detergent solution, a film with a mixture containing a cationic compound and a neutral or zwitterionic lipid, such as for example DOPE.
- the ratio between the positive charges of the cationic lipid and the negative charges of the active substance is between 0 , 05 and 20, in particular between 0.1 and 15 and preferably between 5 and 10.
- This ratio between the number of positive charges of the compound (s) and / or cationic compositions and the number of negative charges of said active substance also constitutes an advantageous characteristic of the complex according to the invention.
- the calculation to arrive at such a ratio will take into account the negative charges carried by the active substance and the amount of compound necessary will be adjusted to satisfy the ratio indicated above.
- the quantities and concentrations for the other components are adjusted by as a function of their respective molar masses and of their number of positive and / or negative charges.
- one or more cationic compounds or compositions are suspended in a buffer and then the suspension is subjected to sonication until visual homogeneity.
- the lipid suspension is then extruded through two microporous membranes under appropriate pressure.
- the lipid suspension is then mixed with a solution of active substance comprising negative charges.
- a film of the mixture of cationic lipid and neutral lipid such as DOPE is formed before suspension, in a known manner.
- This so-called sonication-extrusion technique is well known in the art.
- the characteristics of the complexes formed can be evaluated by several means making it possible to determine, for example: the state of complexation with the active substance, in particular by searching for free nucleic acids by electropnoresis on agarose gel in the case where the substances are nucleic acids, -the size of the particles by quasi-elastic light scattering,
- the present invention also relates to the complexes obtained by the implementation of the methods listed above.
- the invention also relates to the use of a compound, a composition or a complex according to the invention for transferring at least one active substance, in particular therapeutically active, more particularly a nucleic acid, into target cells, in in vitro, ex vivo or in vivo, more particularly in vivo.
- active substance in particular therapeutically active, more particularly a nucleic acid
- target cells prokaryotic cells, yeast cells and eukaryotic cells, plant cells, human or animal cells, and in particular mammalian cells. Mention should also be made of cancer cells.
- the invention can be applied to the interstitial or luminal space of tissues such as the lung, the trachea, the skin, the muscle, the brain, the liver, the heart, the spleen, the bone marrow, thymus, bladder, lymph, blood, pancreas, stomach, kidney, ovaries, testes, rectum, peripheral or central nervous system, eyes, lymphoid organs, cartilage, endothelium.
- the target cell will be a muscle cell, a hematopoietic stem cell or even an airway cell, more particularly a tracheal or pulmonary cell, and advantageously a cell of the respiratory epithelium.
- the complexes according to the invention can be used as a medicament, for curative, preventive or vaccine purposes. This is why the invention also relates to the complexes of the invention as a medicament for curative, preventive or vaccine purposes.
- Such complexes can be used in a method of therapeutic treatment consisting in transferring at least one therapeutically active substance, in particular a polynucleotide, in target cells, in particular a mammalian cell, and more precisely a muscle cell, a hematopoietic stem cell, an airway cell, more particularly a tracheal or pulmonary cell, a cell of the respiratory epithelium.
- a compound according to the invention is very particularly advantageous for transferring a nucleic acid into a muscle cell or a lung cell. This is the compound noted pcTG37 (see example).
- the present invention also relates to a method for introducing an active substance comprising negative charges inside a cell, in particular in vitro, characterized in that cells, in particular cultured on an appropriate medium, are brought into contact with a cationic compound / active substance complex comprising at least one negative charge according to the invention, in particular in the form of a suspension of complexes. After a certain incubation time, the cells are washed and recovered. Verification of the introduction of the active substance can be carried out (possibly after lysis of the cell) by any suitable means.
- introduction process is well known per se.
- introduction is meant that the active substance comprising negative charges is transferred into the cell and is located, at the end of the process, inside said cell or at the level of the membrane thereof.
- the active substance is a nucleic acid
- verification of the transfection of the nucleic acid may be carried out by any appropriate means, for example by measuring the expression of the gene considered or the concentration of the expressed protein.
- the invention relates more particularly to the use of a compound, composition or complex according to the invention for preparing a medicament for curative, preventive o "u vaccine for the treatment of the human body or animal, in particular by gene therapy.
- the medicament can be administered directly in vivo (for example into a muscle, into the lungs by aerosol, etc.). It is also possible to adopt the ex vivo approach which consists in taking cells from the patient (stem cells from the bone marrow, lymphocytes in the peripheral blood, muscle cells, etc.), transfecting them in vitro according to the present invention and re-administering them. to the patient.
- the complexes according to the invention can be administered by intramuscular, intratracheal, intranasal, intracerebral, intrapleural, intratumoral, intracardiac, intragastric, intraperitoneal, epidermal, intravenous, intraarterial syringe or any other equivalent means, systems suitable for the treatment of airways or mucous membranes such as inhalation, instillation, or aerosolization. Mention may also be made of the modes of administration by application of a cream, by oral administration or any other means perfectly known to those skilled in the art and applicable to the present invention.
- a complex according to the invention prepared so as to adjust the compound or composition / therapeutically active substance ratio in said complex, the apparent charge of the complex (see in particular Liu et al, 1997, Gene Therapy, 4, 517-523; Thierry et al., 1995, PNAS, 92, 9742-9746).
- the invention also relates to a method of gene therapy comprising administering to a patient an amount appropriate of a composition according to the invention.
- a method of gene therapy comprising administering to a patient an amount appropriate of a composition according to the invention.
- the administration may take place in a single or repeated dose one or more times after a certain period of time.
- the repeated administration would make it possible to reduce the quantity of therapeutically active substance, of DNA more particularly, to be administered for a given dose
- the route of administration and the appropriate dosage vary according to various parameters, for example the individual or the disease to be treated or the polynucleotide to be transferred.
- the invention relates more particularly to a pharmaceutical preparation comprising at least one complex as described above, optionally also containing at least one adjuvant capable of stabilizing said pharmaceutical preparation for storage, for example, and / or of improving the transfection power. of said complex.
- an adjuvant could for example be chosen from the group consisting of chloroquine, a polar protic compound chosen in particular from propylene glycol, polyethylene glycol, glycerol, ethanol, 1-methyl L -2-pyrrolidone or their derivatives , or an aprotic polar compound chosen in particular from dimethylsulfoxide (DMSO), diethylsulfoxide, di-n-propylsulfoxide, dimethylsulfone, sulfolane, dimethylformamide, dimethylacetamide, tetramethylurea, acetonitrile or their derivatives.
- said preparation may contain a pharmaceutically acceptable carrier allowing its administration to humans or animals.
- the invention relates to a cell transfected with a complex as defined above, particularly a prokaryotic cell, a yeast or eukaryotic cell, in particular an animal cell, in particular a mammalian cell, and more particularly a cancer cell.
- said cell is an airway cell, more particularly a tracheal or pulmonary cell, and advantageously a cell of the respiratory epithelium.
- FIG. 2 indicates the results observed after intravenous injection of complexes according to the invention, the luciferase activity is indicated in RLU / mg of protein).
- the amino groups of the reaction product are protected by 99 mmol of BOC-ON [(2-boc-oxyimino) -2-phenylacetonitrile] (Fluka; reference 15475) in 50 ml of solvent CH 2 C1 2 / CH 3 0H 2 / 1.
- the protective reaction is left overnight at room temperature.
- the solvents are evaporated and the product is taken up in 75 ml of ethyl acetate for 3 extractions with 75 ml of 1M NaOH.
- the organic phase is again extracted with 5% citric acid, then dried and filtered over Na 2 S0 before evaporation to dryness.
- the nitriles reduction step is carried out, in ether at 0 ° C., in the presence of 20 mmol of L1AIH4 (Sigma; L0260). After 30 hours, the reaction is stopped by adding 20 ml of 1M NaOH at 0 ° C, with evolution of hydrogen. The mixture is filtered and extracted 3 times with a solution of 20% NaCl in water. After drying of the ethereal fraction, the product is deposited on a silica column in a solvent CH 2 C1 2 / CH 3 0H 2/1, then eluted in a solvent CH 2 C1 2 / CH 3 0H / (C 2 H 5 ) 3 N 15/5/1.
- the Fmoc groups are removed from the product in a solution of 20% piperidine, 20% tetrahydrofuran and 60% CH 2 C1 2 for 1 hour. After evaporation, a further purification is carried out on a silica column in a solvent CH 2 C1 2 / CH 3 0H 1/1. The fractions containing the product are determined by thin layer chromatography. The product is dried before the last coupling.
- 510 ⁇ mol of the N-hydroxysuccinimide ester of oleic acid (Sigma 0 9506) diluted in 5 ml of anhydrous CH 2 C1 2 is added .
- the amounts of lipids are calculated based on the concentration of final DNA (0.1 mg / ml for the in vitro tests), the desired charge ratio, the molar mass and the number of positive charges for the cationic lipid chosen.
- 0.1 mg DNA / ml or (0.1 / 330) mmol of negative charges correspond to 0.30 ⁇ mol / ml of negative charges.
- a concentration of 3.0 ⁇ mol / ml of positive charges provided by the cationic lipid is required.
- the molar mass of pcTG37 in the form of trifluoroacetate is 988 g / mol and the molecule contains 2 positive charges. So 1.5 ⁇ mol / ml of pcTG37 is required, which corresponds to 1.49 mg / ml.
- the lipids are taken up in chloroform, dried by evaporation then solubilized in chloroform / methanol (v: v) and again dried.
- the cationic lipids are weighed and the amount of DOPE is added from a stock solution of 10 or 20 mg / ml in chloroform in a glass tube sterilized with alcohol and UV to obtain a concentration of 2 mM in cationic lipid.
- the solvents are evaporated in vacuo (0.2.105
- the lipid film is taken up in ethanol to be at the concentration of 50 mg / ml in cationic lipid.
- This solution is completed with 270 ⁇ l of 20 mM HEPES pH 7.5 (adjusted with NaOH) to prepare a solution at 5 mg / ml final.
- the plasmid DNA is prepared from a 1 mg / ml stock solution (10 mM Tris, 1 mM EDTA, pH 7.5).
- lipids are added to the DNA.
- the suspension is mixed by aspiration / delivery with a pipette (10 times).
- the complexes are stored at + 4 ° C.
- 150 ⁇ l of pcTG37 / DOPE are added to 350 ⁇ l of the DNA solution to obtain 0.5 ml of 0.1 mg / ml DNA complex and a charge ratio of 10.
- the preparation of the complexes is done under a laminar flow hood.
- the complexes are obtained according to the same protocol as above.
- lipid film is taken up in a solution of n-octyl, ⁇ -D-glucopyranoside (octylglucoside, Sigma, 0 9882) according to a cationic lipid / detergent ratio of 1/5 (mole: mole).
- plasmid DNA is prepared from a mother solution of plasmid DNA at 1 mg / ml from which 50 ⁇ l are taken for a final volume of 0.5 ml (0.1 mg / ml final) to which 262 are added, 5 ⁇ l of 20 mM HEPES pH 7.5.
- 187.5 ⁇ l of the lipid suspension are added to the DNA by aspirating and discharging 10 times with a pipette to obtain the final suspension at 0.1 mg / ml in DNA and a charge ratio +/- of 10.
- pH 7.5 dialysis microdiigts (exclusion threshold of 13.2 kD; Sartorius, Gôttingen, Germany).
- the complexes DNA / dialyzed lipids are stored at + 4 ° C. The preparation is done in a laminar flow hood.
- the amounts of lipids are calculated as described above based on the concentration of final DNA (0.1 mg / ml for the in vitro tests), the desired charge ratio, the molar mass and the number of positive charges. of the cationic lipid chosen.
- the mixing of the lipids is done in a glass tube sterilized with alcohol and UV, to obtain a 2 mM solution of cationic lipid, as indicated above.
- the solvents are evaporated and the lipid film is taken up in 900 ⁇ l of 20 mM HEPES pH 7.5 at 4 ° C for approximately 16 h.
- the suspension is sonicated in a sonication bath (Bransonic 221) until visual homogeneity.
- the lipid suspension is extruded through two membranes of 0.2 ⁇ m pore diameter (Nucleopore, Costar, Cambridge, MA, USA) and rinsed with HEPES 20mM pH 7.5 (Extruder from Lipex Biomembranes, Vancouver, Canada) at a maximum pressure of 50 bars.
- the lipid suspension is kept at room temperature for 1 hour.
- 450 ⁇ l of the lipid suspension are added to 50 ⁇ l of a mother solution of the plasmid DNA (1 mg / ml) and mixed by suction / delivery 10 times with a pipette.
- the lipid / DNA complexes are stored at + 4 ° C.
- the preparations are made in a laminar flow hood. Protocol for the evaluation of DNA complexation by lipids
- a 1% gel (w: v) of agarose is prepared in a TAE buffer (TAE: Tris " -4, 86g / l + sodium acetate 0.68g / l + EDTA 0.336g / l pH 7.8. If necessary, the sample is diluted in TAE then the blue sample buffer of bromophenol 0.083%, cyanol xylene FF 0.083%, glycerol 10% in water) is added so as to be at 50 ng of DNA / ⁇ l. The sample is briefly subjected to a vortex and left for 30 min at room temperature. As a control, the uncomplexed plasmid prepared at the same concentration is used.
- the analyzes are carried out on a Coulter N4Plus (Coultronics France S.A., Margency, France) at 25 ° C after equilibration of the sample for 20 min. An aliquot of the sample is aspirated and discharged several times before being pipetted. the sample is diluted in the measuring tank and homogenized.
- Coulter N4Plus Coultronics France S.A., Margency, France
- the measurement of the diffracted light at 90 ° is made for 180 sec after 180 sec of waiting.
- the range used goes from 3 nm to
- the cells are seeded 24 h to 48 h before transfection in a 96-well culture dish at a rate of 5 ⁇ 10 3 to 10 4 cells per well, at approximately 30% confluence, and maintained at 37 ° C. in an atmosphere containing 5% C0 2 and 95% air.
- Transfections are performed with mixtures of varying amounts of lipid and plasmid DNA to determine charge ratios and optimal DNA concentrations per well.
- the complexes used are prepared 24 h to 48 h before transfection and diluted in HamF 14 medium containing 40 ⁇ g / ml of gentamycin and 2 mM glutamine.
- A549 cells Transfection of A549 cells with lipid complexes
- the A549 cells are cultured in Eagle's medium modified by Dulbecco (DMEM) containing 10% fetal calf serum (Gibco BRL) 24 hours before the start of transfection in 96-well plates (2 ⁇ 10 4 cells per well) in a humid atmosphere at 37 ° C. and 5% CO 2 /95% air.
- DMEM Dulbecco
- Gibco BRL 10% fetal calf serum
- lipid / DNA complexes are prepared in another microplate (lipid / DNA complexes at 0.1 mg / ml of DNA and at the indicated charge ratio): 44 ⁇ l (4.4 ⁇ g DNA), 22 ⁇ l ( 2.2 ⁇ g DNA), 5.5 ⁇ l (0.55 ⁇ g DNA) of stock solution in the first 3 wells, and 11 ⁇ l (0.11 ⁇ g DNA) of the stock solution diluted 10 times in the next well.
- the volume is made up to 110 ⁇ l with DMEM and 100 ⁇ l are transferred to the A549 cells. Incubation is carried out with 4, 2, 0.5 and 0.1 ⁇ g of DNA per well for 4 hours.
- DMEM + 30% of fetal calf serum 50 ⁇ l of DMEM + 30% of fetal calf serum are added 4 hours after the start of the transfection then 100 ⁇ l of DMEM + 10% of FCS 24 hours after the start of the transfection.
- the transfections in the presence of 10% of fetal calf serum are carried out in an identical manner except that the transfection takes place in medium with serum.
- the cationic lipid preparations pcTG37 were evaluated by in vitro transfection using A549 cells and primary dog myoblasts.
- the intermediate NN '(di-boc) N, N' (dipropionitrile) 1, 4-diaminobutane is obtained by reaction of 37.6 mmol of diaminobutane (Fluka; reference 32790) diluted in 3.8 ml of dichloromethane + 2 ml of methanol at 0 ° C with 75.2 mmol of acrylonitrile (Fluka; reference 01710), one hour at 0 ° C.
- the reaction product is blocked with 100 mmoles of BOC-ON [(2-boc-oxyimino) -2-phenylacetonitrile] (Fluka; reference 15475) in 50 ml of solvent CH 2 Cl 2 / CH 3 OH 2/1.
- the blocking reaction is placed overnight at room temperature.
- the solvents are evaporated and the product is taken up in 200ml of ethyl acetate and then subjected to 3 extractions with 200ml of 1M NaOH.
- the organic phase is again extracted with 5% citric acid, dried and filtered over Na 2 S0 4 before evaporation to dryness.
- a nitrile reduction step is then carried out in ether at 0 ° C., in the presence of 260 mmol of LiAlH4 (Sigma; L0260). After 15 hours, the reaction is stopped by adding 100 ml of 1M sodium hydroxide at 0 ° C, with evolution of hydrogen. The mixture is filtered and extracted
- N, N 'diboc-spermidine The fractions containing N, N 'diboc-spermidine are determined by chromatography on RP-HPLC. A pure part of N, N ′ di-boc-spermidine is thus isolated from the other position isomers of di-boc-spermidine.
- the reaction product is blocked with 109 mmoles of BOC-ON [(2-boc-oxyimino) -2-phenylacetonitrile] (Fluka; reference 15475) in 50 ml of solvent CH 2 C1 : / CH 3 0H 2/1.
- the blocking reaction is placed overnight at room temperature.
- the solvents are evaporated and the product is taken up in 300ml of ethyl acetate for 3 extractions with 300ml of 1M NaOH.
- the organic phase is again extracted with 5% citric acid, dried and filtered over Na 2 S0 before evaporation to dryness.
- the nitriles reduction step is then carried out in ether at 0 ° C.
- the activated ester precipitates on addition and the reaction proceeds in heterogeneous phase for 15 hours with stirring at room temperature. And the same purification protocol (see N- ⁇ -N- ⁇ -Di [oleylamido] -propionic acid) is applied. Weighing: 0.14 g (0.15 mmol), yield: 15%.
- the final product, taken up in 10ml CH 2 C1 2 is deprotected Boc by adding dropwise at 0 ° C 50ml of trifluoroacetic acid (Fluka 91699) redistilled at 72 ° C and diluted in 50ml CH 2 Cl 2 . After 4 hours, the mixture is evaporated 2 times at reduced pressure after dilution in 50 ml of n-hexane.
- the product is taken up in 10 ml of ether, precipitated in hexane and filtered on filter paper. The product is taken up by washing the paper in a solvent CH 2 C1 2 / CH 3 0H 1/1. Controls on TLC (ethyl acetate), HPLC and NMR. Evaporation and weighing: 670 mg (0.68 mmol) yield: 47%.
- Des- complexes according to the invention were synthesized according to the methods described above from the compound pcTG337, in the presence or in the absence of DOPE (2: 1, mol: mol), at a fixed charge ratio of 5, using a plasmid containing the luciferase gene pTG11033 (French patent application No. 97/08267).
- mice used are female C57BL / 6 mice from 9 to 11 weeks old.
- the mice are pretreated by injection of 50 ⁇ l of a preparation of chlodronate encapsulated in a liposome (see Van Rooijen and Sanders, 1994, J. Immunol. Methods, 174, 83-93) incorporated into a total volume of 200 ⁇ l (+ 150 ⁇ l of PBS buffer).
- Intravenous injections are carried out in the tail after disinfection of the skin with 70% ethanol.
- the volume injected is 250 ⁇ l and the quantity of DNA is 60 ⁇ g, the quantity of lipid is 345 ⁇ g.
- mice Two days after the injections, the mice are sacrificed. After extraction, the tissues are frozen in liquid nitrogen and stored at -80 ° C. In order to measure the luciferase activity, the tissues are mechanically ground using a pestle in a mortar placed on the dry ice. 500 ⁇ l of a lysis buffer (Promega) are added to the tissue debris obtained from the lungs and subjected to three stages of freezing / thawing. Cellular debris is removed by centrifugation and the luciferase activity (in RLU / min, relative light unit per minute) is measured on 20 ⁇ l of supernatant according to the supplier's instructions (Promega) by adding 100 ⁇ l of reagent and measuring l by luminescence.
- a lysis buffer Promega
- the luciferase activity measured is standardized with respect to the protein quantity using a standard range produced from commercially available luciferase (Promega).
- the amount of total protein is, moreover, determined by the colorimetric method of bicinchoninic acid. BCA (Smith et al., 1985, Anal. Biochem., 150, 76-85 Pierce) from an aliquot of supernatant. This makes it possible "to express the luciferase activity in RLU per milligram of protein extracted from the tissues.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/171,845 US6335199B1 (en) | 1997-02-28 | 1998-02-27 | Lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use |
JP10537387A JP2000510871A (ja) | 1997-02-28 | 1998-02-27 | 少なくとも一種の活性物質特にポリヌクレオチドを標的細胞中へ移送するのに使用できる新規脂質化合物およびこれを含む組成物、ならびに遺伝子治療における使用 |
CA002252942A CA2252942A1 (fr) | 1997-02-28 | 1998-02-27 | Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
EP98912565A EP0948360A1 (fr) | 1997-02-28 | 1998-02-27 | Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
AU67352/98A AU727040B2 (en) | 1997-02-28 | 1998-02-27 | New lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9702420A FR2760193B1 (fr) | 1997-02-28 | 1997-02-28 | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules |
FR97/02420 | 1997-02-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/171,845 A-371-Of-International US6335199B1 (en) | 1997-02-28 | 1998-02-27 | Lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use |
US10/021,421 Continuation US20020151070A1 (en) | 1997-02-28 | 2001-12-19 | Lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998037916A1 true WO1998037916A1 (fr) | 1998-09-03 |
Family
ID=9504295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/000389 WO1998037916A1 (fr) | 1997-02-28 | 1998-02-27 | Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
Country Status (7)
Country | Link |
---|---|
US (2) | US6335199B1 (fr) |
EP (1) | EP0948360A1 (fr) |
JP (1) | JP2000510871A (fr) |
AU (1) | AU727040B2 (fr) |
CA (1) | CA2252942A1 (fr) |
FR (1) | FR2760193B1 (fr) |
WO (1) | WO1998037916A1 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7910110B2 (en) | 2002-10-02 | 2011-03-22 | Bigdna Limited | Bacteriophage-mediated immunisation against hepatitis |
WO2012001075A2 (fr) | 2010-07-02 | 2012-01-05 | Transgene | Lignees cellulaire aviaires immortalisées |
WO2018093932A2 (fr) | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Acides nucléiques pour le traitement d'allergies |
WO2018195527A1 (fr) | 2017-04-22 | 2018-10-25 | Immunomic Therapeutics, Inc. | Constructions améliorées de lamp |
WO2018204534A1 (fr) | 2017-05-02 | 2018-11-08 | Immunomic Therapeutics, Inc. | Constructions de lamp (protéine membranaire associée au lysosome) comprenant des antigènes cancéreux |
WO2019222281A1 (fr) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc | Constructions améliorées de lamp comprenant des allergènes |
WO2020144615A1 (fr) | 2019-01-10 | 2020-07-16 | Janssen Biotech, Inc. | Néo-antigènes de la prostate et leurs utilisations |
WO2021077051A1 (fr) | 2019-10-18 | 2021-04-22 | Immunomic Therapeutics, Inc | Constructions améliorées de lamp comprenant des antigènes du cancer |
WO2021099906A1 (fr) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccins basés sur les mutants du gène calr et de la protéine jak2 et leurs utilisations |
WO2022009049A1 (fr) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
WO2022009051A1 (fr) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Procédé de détermination de la réactivité à un traitement du cancer de la prostate |
WO2022009052A2 (fr) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
WO2023201201A1 (fr) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Constructions de lamp bicistroniques comprenant des gènes améliorant la réponse immunitaire et leurs procédés d'utilisation |
US12018289B2 (en) | 2020-11-13 | 2024-06-25 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030069173A1 (en) * | 1998-03-16 | 2003-04-10 | Life Technologies, Inc. | Peptide-enhanced transfections |
CA2350882C (fr) | 1998-11-12 | 2011-02-22 | Invitrogen Corporation | Reactifs de transfection |
US6184035B1 (en) * | 1998-11-18 | 2001-02-06 | California Institute Of Technology | Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells |
US7008791B1 (en) * | 1999-10-01 | 2006-03-07 | Lipoxen Technologies Limited | Liposome-entrapped DNA oral vaccines |
WO2001042200A1 (fr) * | 1999-12-10 | 2001-06-14 | Genzyme Corporation | Amphiphiles cationiques pour administration intracellulaire de molecules therapeutiques |
US20020142304A1 (en) * | 2001-03-09 | 2002-10-03 | Anderson Daniel G. | Uses and methods of making microarrays of polymeric biomaterials |
EP1912679A4 (fr) | 2005-06-15 | 2009-07-29 | Massachusetts Inst Technology | Lipides contenant des aminés et utilisations |
MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
WO2010126376A1 (fr) * | 2009-04-30 | 2010-11-04 | Bakteriefritt As | Composition pour la stérilisation de surfaces |
EP3318248B1 (fr) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Administration d'arnm pour l'augmentation des protéines et des enzymes dans des maladies génétiques humaines |
EP2609135A4 (fr) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | Poly(bêta-amino-alcools), leur préparation et utilisations de ceux-ci |
US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
NZ719345A (en) | 2011-06-08 | 2023-03-31 | Translate Bio Inc | Lipid nanoparticle compositions and methods for mrna delivery |
EP2859102A4 (fr) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | Polynucléotides résistant à la nucléase et leurs utilisations |
WO2014028487A1 (fr) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Lipidoïdes contenant des amines et leurs utilisations |
WO2014152966A1 (fr) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Procédés de purification d'arn messager |
PL2968586T3 (pl) | 2013-03-14 | 2019-01-31 | Translate Bio, Inc. | Kompozycje mrna cftr i związne z nimi sposoby i zastosowania |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
CN112656954A (zh) | 2013-10-22 | 2021-04-16 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
CN105658242A (zh) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | 用于苯丙酮尿症的mrna疗法 |
WO2015061500A1 (fr) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Thérapie arnm pour déficience en argininosuccinate synthétase |
WO2015164773A1 (fr) | 2014-04-25 | 2015-10-29 | Shire Human Genetic Therapies, Inc. | Procédés de purification de l'arn messager |
WO2015184256A2 (fr) | 2014-05-30 | 2015-12-03 | Shire Human Genetic Therapies, Inc. | Lipides biodégradables pour l'administration d'acides nucléiques |
EP3160959B1 (fr) | 2014-06-24 | 2023-08-30 | Translate Bio, Inc. | Compositions enrichies stéréochimiquement pour l'administration d'acides nucléiques |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
EP3169310A1 (fr) | 2014-07-15 | 2017-05-24 | Life Technologies Corporation | Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules |
MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
CN112930396B (zh) | 2018-08-24 | 2024-05-24 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016024A1 (fr) * | 1990-04-19 | 1991-10-31 | Vical, Inc. | Lipides cationiques servant a l'apport intracellulaire de molecules biologiquement actives |
WO1994005624A1 (fr) * | 1992-08-28 | 1994-03-17 | Life Technologies, Inc. | Lipides cationiques |
WO1996040726A1 (fr) * | 1995-06-07 | 1996-12-19 | Genta Incorporated | Nouveaux lipides cationiques a base de carbamate |
WO1997003939A1 (fr) * | 1995-07-21 | 1997-02-06 | Genta Incorporated | Nouveaux lipides cationiques a base d'amides |
WO1997031934A2 (fr) * | 1996-02-29 | 1997-09-04 | Chemicon Laboratories Gmbh | Nouvelles lipopolyamines metabolisables, leur preparation et leur utilisation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-02-28 FR FR9702420A patent/FR2760193B1/fr not_active Expired - Fee Related
-
1998
- 1998-02-27 US US09/171,845 patent/US6335199B1/en not_active Expired - Fee Related
- 1998-02-27 JP JP10537387A patent/JP2000510871A/ja active Pending
- 1998-02-27 CA CA002252942A patent/CA2252942A1/fr not_active Abandoned
- 1998-02-27 EP EP98912565A patent/EP0948360A1/fr not_active Withdrawn
- 1998-02-27 AU AU67352/98A patent/AU727040B2/en not_active Ceased
- 1998-02-27 WO PCT/FR1998/000389 patent/WO1998037916A1/fr not_active Application Discontinuation
-
2001
- 2001-12-19 US US10/021,421 patent/US20020151070A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016024A1 (fr) * | 1990-04-19 | 1991-10-31 | Vical, Inc. | Lipides cationiques servant a l'apport intracellulaire de molecules biologiquement actives |
WO1994005624A1 (fr) * | 1992-08-28 | 1994-03-17 | Life Technologies, Inc. | Lipides cationiques |
WO1996040726A1 (fr) * | 1995-06-07 | 1996-12-19 | Genta Incorporated | Nouveaux lipides cationiques a base de carbamate |
WO1997003939A1 (fr) * | 1995-07-21 | 1997-02-06 | Genta Incorporated | Nouveaux lipides cationiques a base d'amides |
WO1997031934A2 (fr) * | 1996-02-29 | 1997-09-04 | Chemicon Laboratories Gmbh | Nouvelles lipopolyamines metabolisables, leur preparation et leur utilisation |
Non-Patent Citations (2)
Title |
---|
A. CZERWINSKI ET AL: "Total synthesis of edeine D", JOURNAL OF ANTIBIOTICS, vol. 36, no. 8, August 1983 (1983-08-01), pages 1001 - 1006, XP002046829 * |
NAOMI SAKAI ET AL: "Total synthesis of galantin I. Revision of the original structure", TETRAHEDRON LETTERS, vol. 31, no. 22, 1990, pages 3183 - 3186, XP002046828 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7910110B2 (en) | 2002-10-02 | 2011-03-22 | Bigdna Limited | Bacteriophage-mediated immunisation against hepatitis |
WO2012001075A2 (fr) | 2010-07-02 | 2012-01-05 | Transgene | Lignees cellulaire aviaires immortalisées |
WO2018093932A2 (fr) | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Acides nucléiques pour le traitement d'allergies |
WO2018195527A1 (fr) | 2017-04-22 | 2018-10-25 | Immunomic Therapeutics, Inc. | Constructions améliorées de lamp |
WO2018204534A1 (fr) | 2017-05-02 | 2018-11-08 | Immunomic Therapeutics, Inc. | Constructions de lamp (protéine membranaire associée au lysosome) comprenant des antigènes cancéreux |
WO2019222281A1 (fr) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc | Constructions améliorées de lamp comprenant des allergènes |
WO2020144615A1 (fr) | 2019-01-10 | 2020-07-16 | Janssen Biotech, Inc. | Néo-antigènes de la prostate et leurs utilisations |
US11793843B2 (en) | 2019-01-10 | 2023-10-24 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2021077051A1 (fr) | 2019-10-18 | 2021-04-22 | Immunomic Therapeutics, Inc | Constructions améliorées de lamp comprenant des antigènes du cancer |
WO2021099906A1 (fr) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccins basés sur les mutants du gène calr et de la protéine jak2 et leurs utilisations |
WO2022009049A1 (fr) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
WO2022009051A1 (fr) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Procédé de détermination de la réactivité à un traitement du cancer de la prostate |
WO2022009052A2 (fr) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Néo-antigènes prostatiques et leurs utilisations |
US12018289B2 (en) | 2020-11-13 | 2024-06-25 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
WO2023201201A1 (fr) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Constructions de lamp bicistroniques comprenant des gènes améliorant la réponse immunitaire et leurs procédés d'utilisation |
Also Published As
Publication number | Publication date |
---|---|
JP2000510871A (ja) | 2000-08-22 |
CA2252942A1 (fr) | 1998-09-03 |
US6335199B1 (en) | 2002-01-01 |
EP0948360A1 (fr) | 1999-10-13 |
AU6735298A (en) | 1998-09-18 |
US20020151070A1 (en) | 2002-10-17 |
FR2760193B1 (fr) | 1999-05-28 |
AU727040B2 (en) | 2000-11-30 |
FR2760193A1 (fr) | 1998-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0948360A1 (fr) | Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique | |
EP0901463B1 (fr) | Composes glycerolipidiques utiles pour le transfert d'une substance active dans une cellule cible | |
US8678686B2 (en) | Multi-chain lipophilic polyamines | |
EP0984925B1 (fr) | Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules | |
WO1998056423A1 (fr) | Nouveaux complexes lipidiques pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique | |
EP0998501B1 (fr) | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique | |
KR20030040441A (ko) | 산 민감성 화합물, 이의 제조방법 및 용도 | |
EP0987029B1 (fr) | Utilisation des polymères cationiques pour la préparation de complexes d' acides nucléiques et compositions apparentées | |
EP1430074B1 (fr) | Derives lipidiques d'aminoglycosides-pour la transfection | |
FR2759367A1 (fr) | Glycerolipides cationiques et complexes de glycerolipides cationiques et de substances actives, notamment pour la transfection de cellules | |
EP0965583A1 (fr) | Composés de polyamine et compositions les contenant, utiles pour le transfert de substances actives dans des cellules | |
FR2766194A1 (fr) | Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique | |
CA2324931A1 (fr) | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications | |
FR2786700A1 (fr) | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations | |
FR2777017A1 (fr) | Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2252942 Country of ref document: CA Ref country code: CA Ref document number: 2252942 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998912565 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 67352/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09171845 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1998912565 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 67352/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998912565 Country of ref document: EP |